Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canakinumab (497) 497
index medicus (262) 262
anakinra (215) 215
humans (193) 193
rheumatology (150) 150
inflammation (112) 112
interleukin-1 (91) 91
male (79) 79
arthritis (78) 78
female (78) 78
efficacy (72) 72
antibodies, monoclonal - therapeutic use (70) 70
familial mediterranean fever (65) 65
rilonacept (64) 64
double-blind (63) 63
cytokines (62) 62
treatment outcome (62) 62
colchicine (58) 58
juvenile idiopathic arthritis (58) 58
gout (54) 54
interleukins (53) 53
pharmacology & pharmacy (52) 52
adult (51) 51
atherosclerosis (51) 51
rheumatoid-arthritis (51) 51
children (48) 48
medicine & public health (48) 48
interleukin-1 receptor antagonist (45) 45
interleukin 1 receptor antagonist protein - therapeutic use (44) 44
interleukin-1beta - antagonists & inhibitors (44) 44
child (43) 43
c-reactive protein (42) 42
immunology (41) 41
middle aged (41) 41
tocilizumab (41) 41
inflammasome (40) 40
adolescent (39) 39
pediatrics (39) 39
safety (39) 39
care and treatment (38) 38
antirheumatic agents - therapeutic use (37) 37
medicine, general & internal (36) 36
disease (35) 35
interleukin 1 (34) 34
management (34) 34
treatment (34) 34
abridged index medicus (33) 33
child, preschool (33) 33
internal medicine (33) 33
amyloidosis (32) 32
autoinflammatory diseases (32) 32
multicenter (32) 32
therapy (32) 32
animals (31) 31
cardiac & cardiovascular systems (31) 31
muckle-wells-syndrome (30) 30
patients (30) 30
placebo-controlled trial (30) 30
cold autoinflammatory syndrome (28) 28
drug therapy (28) 28
interleukin-1 - antagonists & inhibitors (28) 28
macrophage activation syndrome (28) 28
mutation (28) 28
systemic juvenile idiopathic arthritis (28) 28
aged (27) 27
il-1 (27) 27
il-1β (27) 27
open-label (27) 27
pathogenesis (27) 27
periodic syndrome (27) 27
research (27) 27
risk factors (27) 27
anti-inflammatory agents - therapeutic use (26) 26
cryopyrin-associated periodic syndrome (26) 26
etanercept (26) 26
medicine (26) 26
patient (26) 26
receptor antagonist anakinra (26) 26
young adult (26) 26
antibodies, monoclonal - adverse effects (25) 25
colchicine - therapeutic use (25) 25
interleukin-1β (25) 25
analysis (24) 24
medicine, research & experimental (24) 24
fever (23) 23
methotrexate (23) 23
cardiovascular diseases (22) 22
genetic aspects (22) 22
health aspects (22) 22
antibodies, monoclonal - administration & dosage (21) 21
cardiovascular disease (21) 21
cryopyrin-associated periodic syndromes - drug therapy (21) 21
familial mediterranean fever - drug therapy (21) 21
gout suppressants - therapeutic use (21) 21
monoclonal antibodies (21) 21
allopurinol (20) 20
cryopyrin-associated periodic syndromes (20) 20
diagnosis (20) 20
follow-up (20) 20
interleukin-1 beta (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (460) 460
German (16) 16
Russian (14) 14
French (8) 8
Japanese (3) 3
Polish (3) 3
Dutch (2) 2
Portuguese (1) 1
Slovenian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Prevention and treatment of gout
by Stamp, Lisa K and Dalbeth, Nicola
Nature reviews. Rheumatology, 12/2018
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cytokines and soluble receptors of the interleukin-1 family in Schnitzler syndrome
by Migliorini, P and Italiani, P and Pratesi, F and Puxeddu, I and Boraschi, D
Scandinavian Journal of Rheumatology, ISSN 0300-9742, 05/2019, Volume 48, Issue 3, pp. 235 - 238
Objectives: Schnitzler syndrome (SchS) is an autoinflammatory disorder characterized by chronic urticaria, fever, and monoclonal gammopathy. The success of... 
CANAKINUMAB | RHEUMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
by Ridker, Paul M
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2018, Volume 72, Issue 25, pp. 3320 - 3331
Life-threatening cardiovascular events occur despite control of conventional risk factors. Inflammation, as measured by high-sensitivity C-reactive protein... 
atherosclerosis | canakinumab | interleukin-1 | CANTOS | inflammation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text IL-1 blockade in autoinflammatory syndromes1
by Jesus, Adriana A and Goldbach-Mansky, Raphaela
Annual Review of Medicine, ISSN 0066-4219, 2014, Volume 65, pp. 223 - 244
Monogenic autoinflammatory syndromes present with excessive systemic inflammation including fever, rashes, arthritis, and organ-specific inflammation and are... 
Hereditary periodic fever syndromes | Interleukin-1 | Canakinumab | Anakinra | Rilonacept | rilonacept | anakinra | hereditary periodic fever syndromes | canakinumab | interleukin-1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Response to: Anakinra for resistant Behcet uveitis: why not?
by Caso, F and Rigante, D and Vitale, A and Lucherini, OM and Cantarini, L
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, ISSN 0392-856X, 07/2014, Volume 32, Issue 4, pp. S171 - S171
CANAKINUMAB | DISEASE | PATIENT | RHEUMATOLOGY
Journal Article
Details down arrow
6. Full Text A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study
by Vitale, Antonio and Insalaco, Antonella and Sfriso, Paolo and Lopalco, Giuseppe and Emmi, Giacomo and Cattalini, Marco and Manna, Raffaele and Cimaz, Rolando and Priori, Roberta and Talarico, Rosaria and Gentileschi, Stefano and de Marchi, Ginevra and Frassi, Micol and Gallizzi, Romina and Soriano, Alessandra and Alessio, Maria and Cammelli, Daniele and Maggio, Maria C and Marcolongo, Renzo and La Torre, Francesco and Fabiani, Claudia and Colafrancesco, Serena and Ricci, Francesca and Galozzi, Paola and Viapiana, Ombretta and Verrecchia, Elena and Pardeo, Manuela and Cerrito, Lucia and Cavallaro, Elena and Olivieri, Alma N and Paolazzi, Giuseppe and Vitiello, Gianfranco and Maier, Armin and Silvestri, Elena and Stagnaro, Chiara and Valesini, Guido and Mosca, Marta and de Vita, Salvatore and Tincani, Angela and Lapadula, Giovanni and Frediani, Bruno and De Benedetti, Fabrizio and Iannone, Florenzo and Punzi, Leonardo and Salvarani, Carlo and Galeazzi, Mauro and Rigante, Donato and Cantarini, Luca and Working Grp Systemic Autoinflammat
Frontiers in Pharmacology, ISSN 1663-9812, 10/2016, Volume 7, p. 380
Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized... 
Treatment | Autoinflammatory disorders | Canakinumab | Anakinra | Interleukin (IL)-1 | treatment | SCHNITZLERS SYNDROME | PERIODIC SYNDROME | JUVENILE IDIOPATHIC ARTHRITIS | interleukin (IL)-1 | RESISTANT BEHCETS-DISEASE | MONOCLONAL-ANTIBODY CANAKINUMAB | autoinflammatory disorders | anakinra | canakinumab | RECEPTOR ANTAGONIST ANAKINRA | FAMILIAL MEDITERRANEAN FEVER | PHARMACOLOGY & PHARMACY | CASE SERIES | ONSET STILLS-DISEASE | TYPE-2 DIABETES-MELLITUS | Off-label prescribing | Practice | Usage | Enzyme inhibitors | Rheumatologists | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text CSF cytokines correlate with aseptic meningitis and blood brain barrier function in Neonatal-Onset Multisystem Inflammatory Disease (NOMID)
: CNS biomarkers in NOMID correlate with CNS inflammation
by Rodriguez-Smith, Jackeline and Lin, Yen-Chih and Tsai, Wanxia Li and Kim, Hanna and Montealegre-Sanchez, Gina and Chapelle, Dawn and Huang, Yan and Sibley, Cailin H and Gadina, Massimo and Wesley, Robert and Bielekova, Bibiana and Goldbach-Mansky, Raphaela
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 6/2017, Volume 69, Issue 6, pp. 1325 - 1336
Cytokines | CSF biomarkers | Canakinumab | Anakinra | NOMID
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome
by Rowczenio, Dorota M and Pathak, Shelly and Arostegui, Juan I and Mensa-Vilaro, Anna and Omoyinmi, Ebun and Brogan, Paul and Lipsker, Dan and Scambler, Thomas and Owen, Roger and Trojer, Hadija and Baginska, Anna and Gillmore, Julian D and Wechalekar, Ashutosh D and Lane, Thirusha and Williams, Rene and Youngstein, Taryn and Hawkins, Philip N and Savic, Sinisa and Lachmann, Helen J
Blood, ISSN 0006-4971, 03/2018, Volume 131, Issue 9, pp. 974 - 981
To date, the pathogenic mechanisms underlying Schnitzler syndrome remain obscure, in particular, the interplay between the monoclonal protein and increased... 
RECEPTOR ANTAGONIST ANAKINRA | EFFICACY | SAFETY | CANAKINUMAB | PERIODIC SYNDROMES | INFLAMMASOME | DISEASE | FOLLOW-UP | HEMATOLOGY | RILONACEPT | MOSAICISM | Immunobiology and Immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Relationship of Interleukin-1 beta Blockade With Incident Gout and Serum Uric Acid Levels
by Solomon, DH and Glynn, RJ and MacFadyen, JG and Libby, P and Thuren, T and Everett, BM and Ridker, PM
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 10/2018, Volume 169, Issue 8, pp. 535 - 535
Background: Although studies have shown that interleukin-1 beta (IL-1 beta) inhibitors can shorten gout attacks, whether they can prevent gout attacks is... 
PATHOGENESIS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | CANAKINUMAB | DISEASE | RISK | NLRP3 INFLAMMASOME | PREVALENCE | HEALTH | ARTHRITIS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh double dagger et's disease-related uveitis: a multicenter retrospective observational study
by Fabiani, C and Vitale, A and Emmi, G and Lopalco, G and Vannozzi, L and Guerriero, S and Gentileschi, S and Bacherini, D and Franceschini, R and Frediani, B and Galeazzi, M and Iannone, F and Tosi, GM and Cantarini, L
CLINICAL RHEUMATOLOGY, ISSN 0770-3198, 01/2017, Volume 36, Issue 1, pp. 191 - 197
This study aimed to evaluate the role of interleukin (IL)-1 inhibitors anakinra (ANA) and canakinumab (CAN) in the treatment of Beh double dagger et's disease... 
MANAGEMENT | EFFICACY | SAFETY | Behcet's disease | RECEPTOR | GEVOKIZUMAB | BEHCETS-DISEASE | RHEUMATOLOGY | Canakinumab | Treatment | Uveitis | LABEL | PATIENT | Anakinra
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke
by Liberale, Luca and Diaz-Cañestro, Candela and Bonetti, Nicole R and Paneni, Francesco and Akhmedov, Alexander and Beer, Jürg H and Montecucco, Fabrizio and Lüscher, Thomas F and Camici, Giovanni G
European Heart Journal, ISSN 0195-668X, 10/2018, Volume 39, Issue 38, pp. 3511 - 3517
Abstract Aims The CANTOS trial underscored the efficacy of selective antibody-based interleukin (IL)-1β inhibition with Canakinumab in secondary prevention of... 
Stroke | Monoclonal antibody | Canakinumab | IL-1β | Middle cerebral artery occlusion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Canakinumab eliminates resistant familial Mediterranean fever in a Japanese girl
by Yasuda, Ryosuke and Mizuochi, Tatsuki and Kitamura, Miyuki and Migita, Kiyoshi and Yamashita, Yushiro
Pediatrics International, ISSN 1328-8067, 11/2019, Volume 61, Issue 11, pp. 1173 - 1174
children | colchicine‐resistant familial Mediterranean fever | canakinumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study
by Emmi, Giacomo and Emmi, Giacomo and Talarico, Rosaria and Talarico, Rosaria and Lopalco, Giuseppe and Lopalco, Giuseppe and Cimaz, Rolando and Cimaz, Rolando and Cantini, Fabrizio and Cantini, Fabrizio and Viapiana, Ombretta and Viapiana, Ombretta and Olivieri, Ignazio and Olivieri, Ignazio and Goldoni, Matteo and Goldoni, Matteo and Vitale, Antonio and Vitale, Antonio and Silvestri, Elena and Silvestri, Elena and Prisco, Domenico and Prisco, Domenico and Lapadula, Giovanni and Lapadula, Giovanni and Galeazzi, Mauro and Galeazzi, Mauro and Iannone, Florenzo and Iannone, Florenzo and Cantarini, Luca and Cantarini, Luca
Clinical Rheumatology, ISSN 0770-3198, 5/2016, Volume 35, Issue 5, pp. 1281 - 1286
Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in Behçet’s disease (BD). This study was aimed at reporting the... 
Therapy | Medicine & Public Health | Biologics | Rheumatology | Anti-interleukin-1 | Behçet’s disease | Canakinumab | Anakinra
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study
by Colafrancesco, Serena and Priori, Roberta and Valesini, Guido and Argolini, Lorenza and Baldissera, Elena and Bartoloni, Elena and Cammelli, Daniele and Canestrari, Giovanni and Cantarini, Luca and Cavallaro, Elena and Cavalli, Giulio and Cerrito, Lucia and Cipriani, Paola and Dagna, Lorenzo and De Marchi, Ginevra and De Vita, Salvatore and Emmi, Giacomo and Ferraccioli, Gianfranco and Frassi, Micol and Galeazzi, Mauro and Gerli, Roberto and Giacomelli, Roberto and Gremese, Elisa and Iannone, Florenzo and Lapadula, Giovanni and Lopalco, Giuseppe and Manna, Raffaele and Mathieu, Alessandro and Montecucco, Carlomaurizio and Mosca, Marta and Piazza, Ilaria and Piga, Matteo and Pontikaki, Irene and Romano, Micol and Rossi, Silvia and Rossini, Maurizio and Ruscitti, Piero and Silvestri, Elena and Stagnaro, Chiara and Talarico, Rosaria and Tincani, Angela and Viapiana, Ombretta and Vitiello, Gianfranco and Fabris, Francesca and Bindoli, Sara and Punzi, Leonardo and Galozzi, Paola and Sfriso, Paolo and Working Grp Systemic
Frontiers in Pharmacology, ISSN 1663-9812, 06/2017, Volume 8, p. 369
Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still's disease (AOSD). Objectives: To evaluate the efficacy and safety... 
Adult-onset Still's disease | Treatment | Canakinumab | Anakinra | Interleukin (IL)-1 | treatment | DIAGNOSIS | PROFILES | EFFICACY | JUVENILE IDIOPATHIC ARTHRITIS | CYTOKINE | interleukin (IL)-1 | SEPSIS | anakinra | RESISTANT | canakinumab | PHARMACOLOGY & PHARMACY | MANIFESTATIONS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis
by Khanna, Dinesh and Khanna, Puja P and Fitzgerald, John D and Singh, Manjit K and Bae, Sangmee and Neogi, Tuhina and Pillinger, Michael H and Merill, Joan and Lee, Susan and Prakash, Shraddha and Kaldas, Marian and Gogia, Maneesh and Perez‐Ruiz, Fernando and Taylor, Will and Lioté, Frédéric and Choi, Hyon and Singh, Jasvinder A and Dalbeth, Nicola and Kaplan, Sanford and Niyyar, Vandana and Jones, Danielle and Yarows, Steven A and Roessler, Blake and Kerr, Gail and King, Charles and Levy, Gerald and Furst, Daniel E and Edwards, N. Lawrence and Mandell, Brian and Schumacher, H. Ralph and Robbins, Mark and Wenger, Neil and Terkeltaub, Robert and American College of Rheumatology
Arthritis Care & Research, ISSN 2151-464X, 10/2012, Volume 64, Issue 10, pp. 1447 - 1461
MULTICENTER | COLCHICINE | TASK-FORCE | ORAL PREDNISOLONE | ACUTE FLARES | DOUBLE-BLIND | INDOMETHACIN | EVIDENCE BASED RECOMMENDATIONS | PHASE-II | RHEUMATOLOGY | ANTIRHEUMATIC DRUGS | Anti-Inflammatory Agents - therapeutic use | Gout Suppressants - therapeutic use | Arthritis, Gouty - drug therapy | Colchicine - therapeutic use | Humans | Arthritis, Gouty - prevention & control
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Anti-IL1 blocking agents in drug-resistant Behcet's syndrome: our little, case series Reply
by Emmi, G and Silvestri, E and Clucciarelli, L and Squatrito, D and Emmi, L
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, ISSN 0392-856X, 07/2014, Volume 32, Issue 4, pp. S172 - S172
CANAKINUMAB | DISEASE | UVEITIS | PATIENT | ANAKINRA | RHEUMATOLOGY
Journal Article
Details down arrow
17. Full Text Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
by Ridker, Paul M and Everett, Brendan M and Thuren, Tom and MacFadyen, Jean G and Chang, William H and Ballantyne, Christie and Fonseca, Francisco and Nicolau, Jose and Koenig, Wolfgang and Anker, Stefan D and Kastelein, John J.P and Cornel, Jan H and Pais, Prem and Pella, Daniel and Genest, Jacques and Cifkova, Renata and Lorenzatti, Alberto and Forster, Tamas and Kobalava, Zhanna and Vida-Simiti, Luminita and Flather, Marcus and Shimokawa, Hiroaki and Ogawa, Hisao and Dellborg, Mikael and Rossi, Paulo R.F and Troquay, Roland P.T and Libby, Peter and Glynn, Robert J and CANTOS Trial Grp and CANTOS Trial Group and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights